The Latest Cardiac and Vascular News
Data from the POWER PAD II Study presented at VIVA will support FDA 510(k) submission in 2026 WALTHAM, Mass.–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, presented the results of the first 95 patients treated in the POWER […]
ompany to host symposia highlighting results of the POWER PAD II U.S. IDE trial WALTHAM, Mass.–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced its schedule of events for the upcoming Transcatheter Cardiovascular Therapeutics (TCT) and Vascular InterVentional Advances […]
New global HQ features over 37,000 square feet that includes R&D and manufacturing BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today the opening of its new global headquarters at 180 Third Avenue in Waltham, Mass. The new 37,811 […]
POWER PAD II IDE trial evaluates safety and efficacy of the Pulse IVL™ system in patients with severely calcified peripheral arterial disease BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it will present 30-day results of its […]
October 15, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has enrolled the first patient(s) in its U.S. pivotal trial for Pulsatile Intravascular Lithotripsy (PIVL) therapy. The POWER PAD […]
August 20, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its Pulse Intravascular Lithotripsy platform, today announced it has entered into a strategic agreement with the Jacobs Institute, a nonprofit medical device […]
June 06, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal […]
BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the appointment of Elizabeth Galle as the company’s new Vice President of Clinical Affairs. She comes to AVS with more than two decades of leadership […]
BOSTON–(BUSINESS WIRE)–AVS (Amplitude Vascular Systems, Inc), an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today the opening of its new global headquarters at 451 D Street in Boston, Mass. The new 9,365-square-foot space in the Seaport District will […]
30-year medical device veteran to lead AVS’ operational direction after long tenure with Boston Scientific BOSTON–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the appointment of Sean Gilligan as the company’s new Chief Operating Officer. He […]
